← Back
Data updated: Jun 28, 2026
HETERO DRUGS LTD
Pharma Pharmaceuticals
HETERO DRUGS LTD is a pharmaceutical company with 5 FDA-approved products.
-
Since
5
Drugs
-
Trials
0
New Drugs (2yr)
HETERO DRUGS LTD's Key Drugs
HETERO DRUGS LTD's core commercial portfolio centers on EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE — its most strategically important drugs approved in the last 15 years.
HETERO DRUGS LTD's Recent FDA Approvals
New NDA/BLA approvals for HETERO DRUGS LTD over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
HETERO DRUGS LTD's Therapeutic Areas
Disease areas where HETERO DRUGS LTD has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
HETERO DRUGS LTD Pipeline Snapshot
Active clinical trials for HETERO DRUGS LTD across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- -
- Latest
- -
- Applications
- 5